Invasive ductal breast carcinoma

Summary

Invasive ductal breast carcinoma (MONDO:0004953) is a cancer (an umbrella term covering 10 Mondo subtypes) with 6 cohort genes (5 CIViC-evidence somatic drivers; 14 ClinVar predisposition records) and 21 clinical trials. The dominant Reactome pathway is HDR through Homologous Recombination (HRR) (4 cohort genes). Top therapeutic interventions include indocyanine green acid form, anastrozole, and atezolizumab.

At a glance

• Classification: Cancer
• Umbrella term: 10 Mondo subtypes
• Cohort genes: 6
• ClinVar variants: 14
• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	invasive ductal breast carcinoma
Mondo ID	MONDO:0004953
EFO	EFO:0000186
DOID	DOID:3008
NCIT	C4194
SNOMED CT	408643008
UMLS	C1412014
MedGen	730612
Is cancer (heuristic)	yes

Also known as: breast invasive ductal carcinoma · infiltrating ductal adenocarcinoma · infiltrating ductal breast carcinoma · infiltrating ductal carcinoma · infiltrating ductal carcinoma of breast · infiltrating ductal carcinoma of the breast · invasive ductal adenocarcinoma · invasive ductal breast carcinoma · invasive ductal carcinoma · invasive ductal carcinoma of breast · invasive ductal carcinoma of the breast · invasive ductal carcinoma, No specific type · invasive ductal carcinoma, NST

Data availability: 14 ClinVar variants.

Disease family

An umbrella term covering 10 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › breast ductal adenocarcinoma › invasive ductal breast carcinoma

Related subtypes (3): breast papillary carcinoma, breast apocrine carcinoma, ductal breast carcinoma in situ

Subtypes (10): breast mucinous carcinoma, breast secretory carcinoma, glycogen-rich clear cell breast carcinoma, acinic cell breast carcinoma, invasive tubular breast carcinoma, scirrhous breast carcinoma, basal-like breast carcinoma, invasive ductal and lobular carcinoma, medullary breast carcinoma, pleomorphic breast carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

14 retrieved; paginated sample, class counts are floors:

6 conflicting classifications of pathogenicity, 4 pathogenic, 3 uncertain significance, 1 likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
37438	NM_007294.4(BRCA1):c.1961del (p.Lys654fs)	BRCA1	Pathogenic	reviewed by expert panel
54894	NM_007294.4(BRCA1):c.3472G>T (p.Glu1158Ter)	BRCA1	Pathogenic	reviewed by expert panel
559993	NM_000059.4(BRCA2):c.6256_6259del (p.Ile2086fs)	BRCA2	Pathogenic	criteria provided, single submitter
559996	NM_000059.4(BRCA2):c.7068dup (p.Leu2357fs)	BRCA2	Pathogenic	criteria provided, single submitter
439009	NM_000059.4(BRCA2):c.8050A>G (p.Lys2684Glu)	BRCA2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
51251	NM_000059.4(BRCA2):c.215A>G (p.Asn72Ser)	BRCA2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
52347	NM_000059.4(BRCA2):c.7522G>A (p.Gly2508Ser)	BRCA2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
545488	NM_000059.4(BRCA2):c.4025G>A (p.Ser1342Asn)	BRCA2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
141032	NM_000251.3(MSH2):c.260C>G (p.Ser87Cys)	MSH2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
180528	NM_003098.3(SNTA1):c.784A>C (p.Thr262Pro)	SNTA1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
559997	NM_000059.4(BRCA2):c.7426G>C (p.Glu2476Gln)	BRCA2	Uncertain significance	criteria provided, single submitter
231830	NM_024675.4(PALB2):c.34GAG[1] (p.Glu13del)	PALB2	Uncertain significance	criteria provided, multiple submitters, no conflicts
4819602	NM_002691.4(POLD1):c.1875G>T (p.Gly625=)	POLD1	Uncertain significance	criteria provided, single submitter
559992	NM_000059.4(BRCA2):c.3074A>G (p.Lys1025Arg)	BRCA2	Likely benign	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 32 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA1	LoF	BLCA,BRCA,MEL,OVT	CIViC #6
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
PALB2	LoF	OVT	CIViC #15013
MSH2			CIViC #3628
POLD1	LoF	BRCA,ESCA	CIViC #4384

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
SNTA1	Orphanet:101016	Romano-Ward syndrome
PALB2	Orphanet:1333	Familial pancreatic carcinoma
PALB2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
PALB2	Orphanet:178	Chordoma
PALB2	Orphanet:227535	Hereditary breast cancer
PALB2	Orphanet:84	Fanconi anemia
MSH2	Orphanet:144	Lynch syndrome
MSH2	Orphanet:252202	Constitutional mismatch repair deficiency syndrome
POLD1	Orphanet:363649	Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome
POLD1	Orphanet:440437	Familial colorectal cancer Type X
POLD1	Orphanet:447877	Polymerase proofreading-related polyposis

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	clinvar
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	clinvar
SNTA1	HGNC:11167	ENSG00000101400	Q13424	Alpha-1-syntrophin	clinvar
PALB2	HGNC:26144	ENSG00000083093	Q86YC2	Partner and localizer of BRCA2	clinvar
MSH2	HGNC:7325	ENSG00000095002	P43246	DNA mismatch repair protein Msh2	clinvar
POLD1	HGNC:9175	ENSG00000062822	P28340	DNA polymerase delta catalytic subunit	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
SNTA1	Alpha-1-syntrophin	Adapter protein that binds to and probably organizes the subcellular localization of a variety of membrane proteins.
PALB2	Partner and localizer of BRCA2	Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks.
MSH2	DNA mismatch repair protein Msh2	Component of the post-replicative DNA mismatch repair system (MMR).
POLD1	DNA polymerase delta catalytic subunit	As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair.

Protein-family classification

Druggable: 0 · Difficult: 4 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	2	5.8×	0.129
Transcription factor	2	2.8×	0.237
Other/Unknown	2	0.6×	0.936

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
SNTA1	Scaffold/PPI	no		PDZ, PH_domain, PH-like_dom_sf
PALB2	Scaffold/PPI	no		WD40/YVTN_repeat-like_dom_sf, PALB2_WD40, WD40_repeat_dom_sf
MSH2	Other/Unknown	no		DNA_mismatch_repair_MutS_C, DNA_mismatch_repair_MutS-lik_N, DNA_mismatch_repair_MutS_core
POLD1	Transcription factor	no	2.7.7.7	DNA-dir_DNA_pol_B_exonuc, DNA-dir_DNA_pol_B_multi_dom, DNA-dir_DNA_pol_B

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ventricular zone	4
secondary oocyte	3
male germ line stem cell (sensu Vertebrata) in testis	2
primordial germ cell in gonad	2
oocyte	2
apex of heart	1
gastrocnemius	1
hindlimb stylopod muscle	1
buccal mucosa cell	1
mucosa of transverse colon	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
SNTA1	266	ubiquitous	marker	apex of heart, hindlimb stylopod muscle, gastrocnemius
PALB2	232	ubiquitous	yes	secondary oocyte, buccal mucosa cell, oocyte
MSH2	278	ubiquitous	marker	secondary oocyte, oocyte, ventricular zone
POLD1	134	ubiquitous	marker	mucosa of transverse colon, ventricular zone, primordial germ cell in gonad

Protein interactions among cohort

Intra-cohort edges: 6.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA1	9,064
PALB2	5,641
BRCA2	4,839
MSH2	4,537
POLD1	4,000
SNTA1	1,499

Intra-cohort edges

A	B	Sources
BRCA1	BRCA2	string_interaction
BRCA1	MSH2	string_interaction
BRCA1	PALB2	biogrid_interaction, intact, string_interaction
BRCA2	MSH2	string_interaction
BRCA2	PALB2	biogrid_interaction, intact, string_interaction
MSH2	POLD1	string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA1	P38398	33
MSH2	P43246	30
BRCA2	P51587	14
POLD1	P28340	6
PALB2	Q86YC2	4

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
SNTA1	Q13424	80.00

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 87. Enrichment computed across 6 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
HDR through Homologous Recombination (HRR)	4	126.9×	9e-07	BRCA1, BRCA2, PALB2, POLD1
Diseases of DNA repair	3	285.5×	3e-06	BRCA1, BRCA2, MSH2
Impaired BRCA2 binding to PALB2	3	228.4×	3e-06	BRCA1, BRCA2, PALB2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	3	211.5×	3e-06	BRCA1, BRCA2, PALB2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	3	211.5×	3e-06	BRCA1, BRCA2, PALB2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	3	211.5×	3e-06	BRCA1, BRCA2, PALB2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	3	196.9×	4e-06	BRCA1, BRCA2, PALB2
Homologous DNA Pairing and Strand Exchange	3	190.3×	4e-06	BRCA1, BRCA2, PALB2
Resolution of D-loop Structures through Holliday Junction Intermediates	3	150.3×	7e-06	BRCA1, BRCA2, PALB2
Defective homologous recombination repair (HRR) due to PALB2 loss of function	2	317.2×	1e-04	BRCA1, BRCA2
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	2	271.9×	1e-04	MSH2, POLD1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	2	271.9×	1e-04	MSH2, POLD1
Diseases of DNA Double-Strand Break Repair	2	271.9×	1e-04	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	2	271.9×	1e-04	BRCA1, BRCA2
DNA Repair	3	49.2×	1e-04	BRCA1, BRCA2, MSH2
Resolution of D-Loop Structures	2	211.5×	2e-04	BRCA1, BRCA2
Homology Directed Repair	2	102.9×	7e-04	BRCA1, BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	2	102.9×	7e-04	BRCA1, BRCA2
Impaired BRCA2 binding to RAD51	2	102.9×	7e-04	BRCA1, BRCA2
Meiosis	2	95.2×	8e-04	BRCA1, BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	2	90.6×	8e-04	BRCA1, BRCA2
DNA Double-Strand Break Repair	2	82.8×	9e-04	BRCA1, BRCA2
Reproduction	2	63.4×	0.002	BRCA1, BRCA2
TP53 Regulates Transcription of DNA Repair Genes	2	60.4×	0.002	BRCA1, MSH2
Meiotic recombination	2	43.3×	0.003	BRCA1, BRCA2
Defective Mismatch Repair Associated With MSH3	1	951.7×	0.003	MSH2
Defective Mismatch Repair Associated With MSH6	1	951.7×	0.003	MSH2
Defective DNA double strand break response due to BRCA1 loss of function	1	951.7×	0.003	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	951.7×	0.003	BRCA1
KEAP1-NFE2L2 pathway	2	40.1×	0.003	BRCA1, PALB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
DNA damage tolerance	2	561.7×	2e-04	BRCA1, MSH2
double-strand break repair	3	101.5×	2e-04	BRCA1, BRCA2, MSH2
double-strand break repair via homologous recombination	3	78.0×	2e-04	BRCA1, BRCA2, PALB2
regulation of DNA damage checkpoint	2	374.5×	3e-04	BRCA1, BRCA2
inner cell mass cell proliferation	2	330.4×	3e-04	BRCA2, PALB2
response to X-ray	2	295.6×	3e-04	BRCA2, MSH2
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	2	165.2×	9e-04	BRCA2, MSH2
DNA repair	3	31.9×	0.001	BRCA1, MSH2, POLD1
cellular response to ionizing radiation	2	137.0×	0.001	BRCA1, BRCA2
somatic recombination of immunoglobulin genes involved in immune response	1	2808.7×	0.004	MSH2
mitotic recombination-dependent replication fork processing	1	1404.3×	0.007	BRCA2
DNA replication proofreading	1	936.2×	0.010	POLD1
somatic recombination of immunoglobulin gene segments	1	702.2×	0.011	MSH2
B cell mediated immunity	1	702.2×	0.011	MSH2
negative regulation of mammary gland epithelial cell proliferation	1	561.7×	0.011	BRCA2
maintenance of DNA repeat elements	1	561.7×	0.011	MSH2
error-free translesion synthesis	1	561.7×	0.011	POLD1
cellular response to indole-3-methanol	1	561.7×	0.011	BRCA1
nucleotide-excision repair, DNA gap filling	1	468.1×	0.011	POLD1
mitotic recombination	1	468.1×	0.011	MSH2
chordate embryonic development	1	468.1×	0.011	BRCA1
positive regulation of isotype switching to IgA isotypes	1	468.1×	0.011	MSH2
negative regulation of centriole replication	1	401.2×	0.012	BRCA1
establishment of protein localization to telomere	1	351.1×	0.012	BRCA2
DNA strand resection involved in replication fork processing	1	351.1×	0.012	BRCA1
response to UV-B	1	312.1×	0.013	MSH2
response to UV-C	1	280.9×	0.014	BRCA2
telomere maintenance via recombination	1	255.3×	0.015	BRCA2
positive regulation of isotype switching to IgG isotypes	1	255.3×	0.015	MSH2
oxidative phosphorylation	1	234.1×	0.015	MSH2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 5

Druggability breadth: 3 of 6 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA1	12	4
BRCA2	0	0
SNTA1	0	0
PALB2	0	0
MSH2	0	0
POLD1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRCA1	13	Binding:9, Functional:4
MSH2	9	Binding:9
POLD1	8	Binding:8

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase
POLD1	2.7.7.7	DNA-directed DNA polymerase

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

12 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	BRCA1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	BRCA2, SNTA1, PALB2, MSH2, POLD1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	BRCA1
PALB2	0	BRCA1
SNTA1	0	—
MSH2	9	—
POLD1	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE2	4
PHASE3	2
PHASE1/PHASE2	2
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01953588	PHASE3	ACTIVE_NOT_RECRUITING	Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT02620280	PHASE3	COMPLETED	Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
NCT04084730	PHASE2	RECRUITING	Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT01100489	PHASE2	WITHDRAWN	Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
NCT01417286	PHASE2	COMPLETED	Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
NCT02365714	PHASE1/PHASE2	TERMINATED	CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT03947151	PHASE2	COMPLETED	Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer
NCT01791478	PHASE1	ACTIVE_NOT_RECRUITING	BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01644669	Not specified	ACTIVE_NOT_RECRUITING	Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
NCT05837767	Not specified	RECRUITING	A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT01038258	Not specified	UNKNOWN	Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy
NCT01409811	Not specified	TERMINATED	Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
NCT01621529	Not specified	COMPLETED	Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer
NCT01706432	Not specified	COMPLETED	Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
NCT01791998	Not specified	WITHDRAWN	Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer
NCT01819233	Not specified	COMPLETED	Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
NCT02186470	Not specified	COMPLETED	Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
NCT04021069	Not specified	UNKNOWN	Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
NCT04349111	Not specified	WITHDRAWN	An Efficacy Study of the Xoft® Axxent® eBx® IORT System® Lite

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INDOCYANINE GREEN ACID FORM	4	2
ANASTROZOLE	4	1
ATEZOLIZUMAB	4	1
DEGARELIX	4	1
FULVESTRANT	4	1
TALIMOGENE LAHERPAREPVEC	4	1
CHEMBL5402818	0	1